Home » Newsletters » BioWorld Science

BioWorld Science

March 31, 2008

View Archived Issues

Remedial agents for renal disorders disclosed in recent NovaCardia patent

Recent Leo patent describes new therapeutic options for hyperparathyroidism

Novel therapeutic agents for cancer reported in recent patent literature

IGFI receptor mutations implicated in human longevity

Levodopa effective when added to behavioral therapy for cocaine dependence

Advanced Cancer Therapeutics signs exclusive license for the University of Louisville's 4-IPP

Metabolon signs agreement for diagnostic test for the accurate dosing of warfarin

Valproic acid derivative with HDAC inhibitory activity shows antitumor activity in vivo

NICE issues positive final appraisal determination of Acomplia for obesity

Metabolex begins phase I clinical trial of MBX-2982 for type 2 diabetes

FluoroPharma signs licensing agreement with MGH in AD diagnosis and treatment

Vivus completes enrollment in phase III EQUIP trial of Qnexa in obese patients

Shire enters copromotion agreement with TAP Pharmaceutical for Lialda in ulcerative colitis

SGX reports results from two phase I clinical trials of SGX-523 in cancer

Omrix initiates phase II clinical trial of fibrin patch in mild to moderate bleeding

NanoViricides to initiate animal trials of HIV therapeutic HivCide-I

Karo Bio initiates second phase IIb clinical study of eprotirome in dyslipidemia

SIGA reports positive results from phase I clinical trial of ST-246 for smallpox

FDA grants approval to Neurologix to initiate phase II clinical trial of gene transfer therapy

Phase II clinical trial results confirm competitive profile of Orexo's OX-17 in GERD

FDA approves Schering-Plough's label revisions for Pegintron and Rebetol in HCV

Mochida's novel CB2 agonist shows analgesic activity in rat inflammatory pain models

Sound raises funds for clinical studies to test oral hearing loss candidate SPI-1005

KY-201 shows better safety profile than rosiglitazone in preclinical studies

AnGes receives approval to manufacture and market Naglazyme for MPS VI

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...